99Tcm标记葡萄糖类衍生物肿瘤代谢显像剂的研究进展

Research Progress of 99Tcm Labeled Glucose Derivatives as Tumor Metabolic Imaging Agents

肿瘤^18F-2-脱氧氟化葡萄糖正电子发射计算机体层显像(^18F-FDG PET)的临床价值已经被广泛认可,但^18F-FDG PET的缺点是费用昂贵且不是特异的显像。近年来,以核医学最常用核素99 Tc m标记葡萄糖类衍生物的研发和临床应用有了明显进展。^99Tc^m标记葡萄糖类衍生物以类似于^18F-FDG的方式被肿瘤细胞摄取,并参与了细胞核的增殖过程。^99Tc^m标记双半胱氨酸氨基脱氧葡萄糖肿瘤显像已经完成了Ⅱ期临床试验,显示出与^18F-FDG显像相似的诊断效能。其他一些新型^99Tc^m标记葡萄糖类衍生物的临床前生物分布研究显示出优越的显像性能,有望完成显像剂研发的突破,使^99Tc^m标记葡萄糖类衍生物显像成为^18F-FDG肿瘤代谢显像的重要补充。

The clinical value of18F-2-deoxy-D-fluoro-glucose positron emission tomograph(18F-FDG PET) tumor imaging has been widely recognized,but its high cost and non-specific imaging constitute its disadvantages. In recent years,the research and clinical application of glucose derivatives labeled with the most commonly used nuclide99Tcmin nuclear medicine have made great progress.99Tcm-labeled glucose derivatives are not only ingested by tumor cells in a manner similar to18F-FDG,but also involved in the process of nuclear proliferation.99Tcm-ethylenedicysteine deoxyglucose has completed phase Ⅱ clinical studies,showing similar diagnostic efficacy to18F-FDG imaging. The preclinical biological distribution studies of other novel99Tcm-labeled glucose derivatives have shown excellent tumor imaging performance and are expected to achieve a breakthrough in the development of imaging agents.99Tcm labeled glucose derivative imaging is becoming an important supplement to18F-FDG tumor metabolism imaging.